Valuation: Evolus, Inc.

Market Cap 463M 413M 382M 346M 648M 43.95B 658M 4.6B 1.82B 23.03B 1.74B 1.7B 72.6B P/E 2026 *
-14.2x
P/E 2027 * -44.9x
Enterprise Value 584M 522M 482M 437M 817M 55.44B 830M 5.8B 2.3B 29.05B 2.19B 2.15B 91.58B EV / Sales 2026 *
1.75x
EV / Sales 2027 * 1.5x
Free-Float
85.03%
Yield 2026 *
-
Yield 2027 * -
1 day-5.40%
1 week-1.27%
Current month-12.38%
1 month-12.38%
3 months+17.03%
6 months+32.02%
Current year+5.41%
1 week 6.93
Extreme 6.93
7.63
1 month 6.91
Extreme 6.9127
8.15
Current year 3.86
Extreme 3.86
9.31
1 year 3.86
Extreme 3.86
9.31
3 years 3.86
Extreme 3.86
17.82
5 years 3.86
Extreme 3.86
17.82
10 years 2.85
Extreme 2.85
39.5
Manager TitleAgeSince
Chief Executive Officer 48 06/05/2018
Director of Finance/CFO 48 08/09/2025
Chief Operating Officer - 01/09/2022
Director TitleAgeSince
Chairman 63 01/01/2018
Director/Board Member 71 12/02/2018
Director/Board Member 48 06/05/2018
Date Insider Type Main position Quantity % Market Cap. Importance
2/9/26 Sell

Chief Executive Officer

-105,108 0.1625%
20/3/26 Sell

Chief Executive Officer

13,669 0.0211%
20/3/26 Sell

Chief Technology Officer

3,119 0.0048%
Change 5-day change 1-year change 3-year change Capi.($)
-5.40%-1.27%+3.85%-9.08% 489M
-2.54%+1.31%+55.10%+120.84% 1,165B
-1.42%+3.23%+37.07%+74.26% 645B
+0.16%+0.08%+25.14%+97.36% 504B
-0.31%+2.95%+39.36%+63.56% 380B
-1.34%-0.47%+66.63%+40.56% 363B
-0.68%+1.67%+22.07%+50.94% 297B
-1.20%+0.99%+2.26%+22.95% 269B
-1.79%+1.57%+49.97%+60.87% 237B
-0.73%-0.10%+29.24%+101.19% 195B
Average -1.14%+1.65%+33.07%+62.34% 405.6B
Weighted average by Cap. -0.25%+2.61%+40.59%+81.87%

Financials

2026 *2027 *
Net sales 334M 298M 276M 250M 467M 31.72B 475M 3.32B 1.31B 16.62B 1.25B 1.23B 52.4B 392M 350M 324M 293M 549M 37.23B 558M 3.89B 1.54B 19.51B 1.47B 1.44B 61.5B
Net income -31.58M -28.2M -26.05M -23.61M -44.17M -3B -44.9M -313M -124M -1.57B -119M -116M -4.95B -9.05M -8.08M -7.46M -6.76M -12.65M -859M -12.86M -89.82M -35.56M -450M -33.95M -33.23M -1.42B
Net Debt 121M 108M 99.82M 90.46M 169M 11.49B 172M 1.2B 476M 6.02B 454M 444M 18.97B 126M 113M 104M 94.2M 176M 11.96B 179M 1.25B 495M 6.27B 473M 463M 19.76B
Projected Income Statement - Annual - Evolus, Inc.
Logo Evolus, Inc.
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
Employees
353
Date Price Change Volume
23/10/26 USD 7.010 -5.40% 597,824
22/10/26 USD 7.410 +0.14% 621,862
21/10/26 USD 7.400 +0.41% 912,577
20/10/26 USD 7.370 +0.14% 447,832
19/10/26 USD 7.360 +3.66% 517,872
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Evolus, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
7.010USD
Average target price
15.00USD
Spread / Average Target
+113.98%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Evolus, Inc.
  1. Stock Market
  2. Stocks
  3. EOLS Stock